A Phase 2 interventional study of VVN461 Ophthalmic Solution 1.0% and VVN461 Ophthalmic Solution 0.5% in Inflammation, sponsored by VivaVision Biotech, Inc. Completed at 10 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by VivaVision Biotech, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,173 studies in Inflammation with a site in United States — 161 open to participants now, 214 under way, 6 of them phase 3. Inflammation · United States.
Among the 1,173 studies in Inflammation with a site in United States, this one is the 245th largest by enrollment of the 956 interventional ones that give a count, is one of 42 that started in 2024, is one of 172 in phase 2, and was the 1,041st registered.
3,541 studies on the registry are indexed under Inflammation; 646 are open to participants now.
Browse Inflammation studies →161 of the 1,173 studies in Inflammation with a site in United States are open now. Recruiting first, the newest first:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
University of Nebraska · Sites in United States
Ages 1 mo–3 yrs
Daniel Moriarity · Sites in United States
Ages 18+
University of Arkansas · Sites in United States
Ages 21–75 · Healthy volunteers
Vanderbilt University Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 160 · Phase 2 241 · Phase 3 91 · Phase 4 73
First in 1978; this study’s year is marked. 42 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is above the median of 50 across 2,582 interventional studies indexed under Inflammation.
Median enrollment 45 across the 956 interventional studies, 90 across the 214 observational. Of the 887 that completed or were terminated, 307 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
164 of 1,173 have an industry lead sponsor. The 10 most frequent:
VivaVision Biotech, Inc is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
VivaVision Biotech, Inc has 1 study filed under Inflammation — fewer than ten, so there is no comparison to draw.
79 of the studies in Inflammation with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT05699174Phase 3Major Extremity Trauma Research ConsortiumPO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation | 2027-09 |
| NCT03675724Mayo ClinicAlleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults | 2026-11 |
| NCT03430037Mayo ClinicAlleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women | 2026-11 |
Add all 79 to your calendar (.ics) → With an account.
Among the 1,173 studies in Inflammation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement (CELR) surgery via phacoemulsification
This is a phase 2, multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the US assessing the safety and ocular efficacy of VVN461 for treating post-operative ocular inflammation in subjects who undergo routine unilateral CELR surgery via phacoemulsification without surgical complication. Approximately 90 subjects (30 per group) will be randomized in a 1:1:1 ratio. Subjects will administer 1 eye drop in the study eye four times a day (QID) for 14 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VVN461 Ophthalmic Solution, 1.0%
Drug: VVN461 Ophthalmic Solution 1.0%
VVN461 Ophthalmic Solution, 0.5%
Drug: VVN461 Ophthalmic Solution 0.5%
VVN461 Vehicle
Drug: Vehicle
Topical ocular drug
Topical ocular drug
Topical ocular drug
Anterior Chamber Cell (ACC): Categorical Cure
Proportion of subjects with grade of 0 using SUN Working Group Grading Scale (0 (none) to 4+ (\>50 cells in field). Note - higher values represent a WORSE outcome.
Time frame: Day 14
Safety of VVN461
Number of subjects with Adverse Events
Time frame: Day 21
| Milestone | VVN461 1.0% | VVN461 0.5% | Vehicle |
|---|---|---|---|
| Started | 30 | 30 | 31 |
| Completed | 30 | 30 | 31 |
| Not completed | 0 | 0 | 0 |
Proportion of subjects with grade of 0 using SUN Working Group Grading Scale (0 (none) to 4+ (\>50 cells in field). Note - higher values represent a WORSE outcome.
| Participants | VVN461 1.0% | VVN461 0.5% | Vehicle |
|---|---|---|---|
| Anterior Chamber Cell (ACC): Categorical Cure | 18 | 16 | 6 |
Number of subjects with Adverse Events
| Participants | VVN461 1.0% | VVN461 0.5% | Vehicle |
|---|---|---|---|
| Safety of VVN461 | 2 | 3 | 3 |
Collected over 21 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VVN461 1.0% | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| VVN461 0.5% | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Vehicle | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Age, Categorical(Participants) | VVN461 1.0% | VVN461 0.5% | Vehicle | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 9 | 7 | 25 |
| >=65 years | 21 | 21 | 24 | 66 |
| Age, Continuous(years) | VVN461 1.0% | VVN461 0.5% | Vehicle | Total |
|---|---|---|---|---|
| Mean | 69.1 ± 7.28 | 68.5 ± 8.51 | 69.8 ± 7.94 | 69.1 ± 6.79 |
| Sex: Female, Male(Participants) | VVN461 1.0% | VVN461 0.5% | Vehicle | Total |
|---|---|---|---|---|
| Female | 14 | 23 | 18 | 55 |
| Male | 16 | 7 | 13 | 36 |
| Race (NIH/OMB)(Participants) | VVN461 1.0% | VVN461 0.5% | Vehicle | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 3 | 5 | 12 |
| White | 23 | 24 | 22 | 69 |
| More than one race | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 1 | 1 | 1 | 3 |
| Region of Enrollment(participants) | VVN461 1.0% | VVN461 0.5% | Vehicle | Total |
|---|---|---|---|---|
| United States | 30 | 30 | 31 | 91 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2024 to primary completion in May 2024, 4 months.
Results were first posted in Jun 2025, 1 year after primary completion.
Of 36 industry-sponsored phase 2 interventional studies under Inflammation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 4 months is below that.
Counting every sponsor, half of 149 studies reached it within 29 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VVN461
VivaVision Biotech, Inc